|Table of Contents|

Correlation between tertiary lymphoid structures scores and class-switched memory B cells in breast cancer microenvironment and its effect on patients survival

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 02
Page:
226-233
Research Field:
Publishing date:

Info

Title:
Correlation between tertiary lymphoid structures scores and class-switched memory B cells in breast cancer microenvironment and its effect on patients survival
Author(s):
ZHU Liangxiao1; DU Yiqiao2; WANG Wenhui2; JIANG Guangjie3; ZHANG Chao4; GAO Fenghou1
1.Department of Oncology,Shanghai Ninth People’s Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 201999,China;2.Clinical Laboratory,Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai,Shanghai 201999,China;3.Department of Laboratory Medicine,Huashan Hospital,Fudan University,Shanghai 200040,China;4.Geriatric Department,Shanghai Ninth People’s Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 201999,China.
Keywords:
breast cancer microenvironment; tertiary lymphoid structures(TLS); class-switched memory B cells(CSM B); multiplex immunofluorescence; survival analysis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2025.02.009
Abstract:
Objective:To investigates the correlation between tertiary lymphoid structures(TLS) scores and overall survival(OS) in the breast cancer microenvironment(TME) and explores the relationship between TLS scores and class-switched memory B cells(CSM B).Methods:Kaplan-Meier survival analysis was conducted on breast cancer patients from The Cancer Genome Atlas (TCGA) database to assess TLS scores and OS and the corration between them and CSM B cells scores.Multiplex immunofluorescence (mIF) staining was utilized to evaluate the development of TLS within the TME.Mann-Whitney U tests and Spearman’s rank correlation coefficients were performed to assess the correlation between CSM B cell distribution in TLS and tumor immune microenvironment scores.Results:Patients with higher TLS scores exhibited significantly improved OS compared to those with lower scores (P<0.05).A positive correlation was observed between TLS scores and CSM B cell scores.Mature germinal centers (GCs) within TLS were rich in CSM B cells,indicating robust humoral immune responses.Patients with higher CSM B cell scores had significantly better tumor immune microenvironment scores（P<0.05）,and the OS of patients in the high CMS B cell scores group was significantly better than that in the low score group（P<0.05）.Conclusion:The presence of CSM B cells in mature TLS is indicative of a key role in local immune responses and underscores the prognostic value and therapeutic potential of these cells in breast cancer.

References:

[1] WANG J,WU SG.Breast cancer:an overview of current therapeutic strategies,challenge,and perspectives［J］.Breast Cancer (Dove Med Press),2023,15:721-730.
[2] WANG Z,KATSAROS D,WANG J,et al.Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival［J］.Sci Rep,2023,13(1):18962.
[3] SATO Y,SHIMODA M,SOTA Y,et al.Enhanced humoral immunity in breast cancer patients with high serum concentration of anti-HER2 autoantibody［J］.Cancer Med,2021,10(4):1418-1430.
[4] FRIDMAN WH,MEYLAN M,PETITPREZ F,et al.B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome［J］.Nat Rev Clin Oncol,2022,19(7):441-457.
[5] DING GY,MA JQ,YUN JP,et al.Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma［J］.J Hepatol,2022,76(3):608-618.
[6] VANHERSECKE L,BRUNET M,GUEGAN JP,et al.Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression［J］.Nat Cancer,2021,2(8):794-802.
[7] STARICH O,RIECK JM,TARTER WJ,et al.Composition of the CD27+ memory-B-cell compartment delineates immunoglobulin deficiency endotypes［J］.Res Sq［Preprint］,2024 Jan 9:rs.3.rs-3838482.doi:10.21203/rs.3.rs-3838482/v1.PMID: 38260264;PMCID:PMC10802728.
[8] GAGO DA GRACA C,VAN BAARSEN LGM,MEBIUS RE.Tertiary lymphoid structures:diversity in their development,composition,and role［J］.J Immunol,2021,206(2):273-281.
[9] JACQUELOT N,TELLIER J,NUTT SL,et al.Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies［J］.Oncoimmunology,2021,10(1):1900508.
[10] VAGHJIANI RG,SKITZKI JJ.Tertiary lymphoid structures as mediators of immunotherapy response［J］.Cancers (Basel),2022,14(15):3748.
[11] WANG B,LIU J,HAN Y,et al.The presence of tertiary lymphoid structures provides new insight into the clinicopathological features and prognosis of patients with breast cancer［J］.Frontiers in Immunology,2022,13:868155.
[12] SOFOPOULOS M,FORTIS SP,VAXEVANIS CK,et al.The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer［J］.Cancer Immunology,Immunotherapy,2019,68:1733-1745.
[13]赵珣.三级淋巴结构与乳腺癌预后的相关性研究［D］.沈阳：中国医科大学,2023. ZHAO X.Study on the correlation between tertiary lymph structure and prognosis of breast cancer［D］.Shenyang:China Medical University,2023.
[14] VELLA G,GUELFI S,BERGERS G.High endothelial venules:a vascular perspective on tertiary lymphoid structures in cancer［J］.Front Immunol,2021,12:736670.
[15] WU Z,ZHOU J,XIAO Y,et al.CD20+CD22+ADAM28+ B cells in tertiary lymphoid structures promote immunotherapy response［J］.Front Immunol,2022,13:865596.
[16] ZOU J,ZHANG Y,ZENG Y,et al.Tertiary lymphoid structures:a potential biomarker for anti-cancer therapy［J］.Cancers (Basel),2022,14(23):5968.
[17] ZHANG Q,WU S.Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response［J］.Front Immunol,2023,13:1063711.
[18] 韩宁,高先春,姚瑞荣,等.三级淋巴结构在恶性实体肿瘤中的研究进展［J］.肿瘤综合治疗电子杂志,2023,9(02):119-128. HAN N,GAO XC,YAO RR,et al.Research progress of tertiary lymphoid structures in malignant solid tumors［J］.Journal of Comprehensive Cancer Therapy,2023,9 (02):119-128.
[19] ESPARCIA-PINEDO L,ROMERO-LAORDEN N,ALFRANCA A.Tertiary lymphoid structures and B lymphocytes:a promising therapeutic strategy to fight cancer［J］.Front Immunol,2023,14:1231315.
[20] TRUB M,ZIPPELIUS A.Tertiary lymphoid structures as a predictive biomarker of response to cancer immunotherapies［J］.Front Immunol,2021,12:674565.
[21] 崔雪,翁一鸣,王培伟,等.三级淋巴结构在肿瘤患者预后及免疫治疗中的价值［J］.实用肿瘤杂志,2023,38(02):190-195. CUI X,WENG YM,WANG PW,et al.The value of tertiary lymphoid structures in the prognosis and immunotherapy of cancer patients［J］.Journal of Practical Oncology,2023,38(02):190-195.
[22] RIZZO A,CUSMAI A,ACQUAFREDDA S,et al.KEYNOTE-522,IMpassion031 and GeparNUEVO:changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer［J］.Future Oncol,2022,18(18):2301-2309.
[23] LIU X,TSANG JYS,HLAING T,et al.Distinct tertiary lymphoid structure associations and their prognostic relevance in HER2 positive and negative breast cancers［J］.Oncologist,2017,22(11):1316-1324.
[24] HAGGLOF T,CIPOLLA M,LOEWE M,et al.Continuous germinal center invasion contributes to the diversity of the immune response［J］.Cell,2023,186(1):147-161.e15.
[25] LIU Y,HU Y,XUE J,et al.Advances in immunotherapy for triple-negative breast cancer［J］.Mol Cancer,2023,22(1):154.
[26] 翁小淇,苏士成,陆艺文.三级淋巴样结构与抗肿瘤免疫［J］.中国细胞生物学学报,2022,44(04):627-638. WENG XQ,SU SC,LU YW.Tertiary lymphoid structure and anti-tumor immunity［J］.Chinese Journal of Cell Biology,2022,44 (04):627-638.

Memo

Memo:
National Natural Science Foundation of China(No.82002922);国家自然科学基金（编号：82002922）
Last Update: 1900-01-01